Evaluation of 12-lipoxygenase (12-LOX) and plasminogen activator inhibitor 1 (pai-1) as prognostic markers in prostate cancer

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Gondek, Tomasz ^a,b   Szajewski, Mariusz ^c,d   Szefel, Jarosław ^c,d   Aleksandrowicz Wrona, Ewa ^d   Skrzypczak Jankun, Ewa ^e   Jankun, Jerzy ^d,e,f   Lysiak Szydlowska, Wieslawa ^d,g  

^a St Vincent a Paulo Hospital   (Poland)

^b Department of Urology Multidisciplinary Hospital Jantar   (Poland)

^c PCK's Maritime Hospital in Gdynia   (Poland)

^d MEDICAL UNIVERSITY OF GDANSK   (Poland)

^e MEDICAL COLLEGE OF OHIO   (United States)

^f KING SAUD UNIVERSITY   (Saudi Arabia)

^g Powi lanski College Faculty of Health Science   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 12 LIPOXYGENASE; BETA THROMBOGLOBULIN; C REACTIVE PROTEIN; HEMOGLOBIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTATE SPECIFIC ANTIGEN; THROMBOPLASTIN; SERPINE1 PROTEIN, HUMAN; TUMOR MARKER;

AGED; ARTICLE; BLOOD CLOTTING; CANCER PROGNOSIS; CONTROLLED STUDY; ERYTHROCYTE COUNT; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERNATIONAL NORMALIZED RATIO; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; THROMBOCYTE COUNT; BLOOD; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

AGED; ARACHIDONATE 12-LIPOXYGENASE; HUMANS; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84899584404     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/102478     Document Type: Article

References (64)

1. Heidenreich A., Bellmunt J., Bolla M., Joniau S., Mason M., Matveev V., Mottet N., Schmid H.-P., van der Kwast T., Wiegel T., Zattoni F., EAU guidelines on prostate cancer-part 1: screening, diagnosis, and treatment of clinically localised disease. European Urology 2011 59 1 61 71 2-s2.0-78649362120 10.1016/j.eururo.2010.10.039
2. Shariat S. F., Karam J. A., Walz J., Roehrborn C. G., Montorsi F., Margulis V., Saad F., Slawin K. M., Karakiewicz P. I., Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clinical Cancer Research 2008 14 12 3785 3791 2-s2.0-50849143820 10.1158/1078-0432.CCR-07-4969
3. Martin S. K., Vaughan T. B., Atkinson T., Zhu H., Kyprianou N., Emerging biomarkers of prostate cancer (Review). Oncology Reports 2012 28 2 409 417 10.3892/or.2012.1832
4. Kelavkar U. P., Glasgow W., Olson S. J., Foster B. A., Shappell S. B., Overexpression of 12/15-lipoxygenase, an ortholog of human 15-lipoxygenase-1, in the prostate tumors of TRAMP mice. Neoplasia 2004 6 6 821 830 2-s2.0-11144350221 10.1593/neo.04286 (Pubitemid 40041501)
5. Mamalakis G., Kafatos A., Kalogeropoulos N., Andrikopoulos N., Daskalopulos G., Kranidis A., Prostate cancer versus hyperplasia: relationships with prostatic and adipose tissue fatty acid composition. Prostaglandins, Leukotrienes and Essential Fatty Acids 2002 66 5-6 467 477 2-s2.0-0036587081 10.1054/plef.2002.0384
6. Ghosh J., Myers C. E., Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. Biochemical and Biophysical Research Communications 1997 235 2 418 423 2-s2.0-0031577170 10.1006/bbrc.1997.6799 (Pubitemid 27313723)
7. Jones R., Adel-Alvarez L.-A., Alvarez O. R., Broaddus R., Das S., Arachidonic acid and colorectal carcinogenesis. Molecular and Cellular Biochemistry 2003 253 1-2 141 149 2-s2.0-0142212372 10.1023/A:1026060426569 (Pubitemid 37321720)
8. Shappell S. B., Olson S. J., Hannah S. E., Manning S., Roberts R. L., Masumori N., Jisaka M., Boeglin W. E., Vader V., Dave D. S., Shook M. F., Thomas T. Z., Funk C. D., Brash A. R., Matusik R. J., Elevated expression of 12/15-lipoxygenase and cyclooxygenase-2 in a transgenic mouse model of prostate carcinoma. Cancer Research 2003 63 9 2256 2267 2-s2.0-0037699032 (Pubitemid 36538635)
9. Szefel J., Piotrowska M., Kruszewski W. J., Jankun J., Łysiak-Szydłowska W., Skrzypczak-Jankun E., Eicosanoids in prevention and management of diseases. Current Molecular Medicine 2011 11 1 13 25 2-s2.0-79551675364 10.2174/156652411794474374
10. Azrad M., Turgeon C., Demark-Wahnefried W., Current evidence linking polyunsaturated fatty acids with cancer risk and progression. Frontiers in Oncology 2013 3 article 224 10.3389/fonc.2013.00224
11. Nie D., Honn K. V., Cyclooxygenase, lipoxygenase and tumor angiogenesis. Cellular and Molecular Life Sciences 2002 59 5 799 807 2-s2.0-0036283215 10.1007/s00018-002-8468-9 (Pubitemid 34628241)
12. Nie D., Che M., Grignon D., Tang K., Honn K. V., Role of eicosanoids in prostate cancer progression. Cancer and Metastasis Reviews 2001 20 3-4 195 206 2-s2.0-0035740016 10.1023/A:1015579209850 (Pubitemid 34595268)
13. Nie D., Hillman G. G., Geddes T., Tang K., Pierson C., Grignon D. J., Honn K. V., Platelet-type 12-lipoxygenase in a human prostate carcinoma stimulates angiogenesis and tumor growth. Cancer Research 1998 58 18 4047 4051 2-s2.0-0032530236 (Pubitemid 28440552)
14. Matsuyama M., Yoshimura R., Mitsuhashi M., Hase T., Tsuchida K., Takemoto Y., Kawahito Y., Sano H., Nakatani T., Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors. International Journal of Oncology 2004 24 4 821 827 2-s2.0-1842841717
15. Pidgeon G. P., Kandouz M., Meram A., Honn K. V., Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells. Cancer Research 2002 62 9 2721 2727 2-s2.0-0036570319 (Pubitemid 34462758)
16. Timár J., Rásó E., Döme B., Li L., Grignon D., Nie D., Honn K. V., Hagmann W., Expression, subcellular localization and putative function of platelet-type 12-lipoxygenase in human prostate cancer cell lines of different metastatic potential. International Journal of Cancer 2000 87 1 37 43 (Pubitemid 30368413)
17. Zhang J., Sud S., Mizutani K., Gyetko M. R., Pienta K. J., Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model. Neoplasia 2011 13 1 23 30 2-s2.0-78650996236 10.1593/neo.10728
18. Duffy M. J., The urokinase plasminogen activator system: role in malignancy. Current Pharmaceutical Design 2004 10 1 39 49 2-s2.0-0347917028 10.2174/1381612043453559 (Pubitemid 38072742)
19. Noh H., Hong S., Huang S., Role of urokinase receptor in tumor progression and development. Theranostics 2013 3 7 487 495 10.7150/thno.4218
20. Jankun J., Skrzypczak-Jankun E., Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride. Cancer Biochemistry Biophysics 1999 17 1-2 109 123 2-s2.0-0032877879 (Pubitemid 29475251)
21. Bekes E. M., Deryugina E. I., Kupriyanova T. A., Zajac E., Botkjaer K. A., Andreasen P. A., Quigley J. P., Activation of pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cells. Neoplasia 2011 13 9 806 821 2-s2.0-80053458622
22. Andreasen P. A., Egelund R., Petersen H. H., The plasminogen activation system in tumor growth, invasion, and metastasis. Cellular and Molecular Life Sciences 2000 57 1 25 40 2-s2.0-0033981473 10.1007/s000180050497 (Pubitemid 30105328)
23. Swiercz R., Wolfe J. D., Zaher A., Jankun J., Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype. Clinical Cancer Research 1998 4 4 869 877 2-s2.0-0031942989 (Pubitemid 28183387)
24. Pepper M. S., Extracellular proteolysis and angiogenesis. Thrombosis and Haemostasis 2001 86 1 346 355 2-s2.0-0034923623 (Pubitemid 32663965)
25. Jankun J., Antitumor activity of the type 1 plasminogen activator inhibitor and cytotoxic conjugate in vitro. Cancer Research 1992 52 20 5829 5832 2-s2.0-0026775997
26. Jankun J., Aleem A. M., Specht Z., Keck R. W., Lysiak-Szydlowska W., Selman S. H., Skrzypczak-Jankun E., PAI-1 induces cell detachment, downregulates nucleophosmin (B23) and fortilin (TCTP) in LnCAP prostate cancer cells. International Journal of Molecular Medicine 2007 20 1 11 20 2-s2.0-34548089505
27. Binder B. R., Mihaly J., The plasminogen activator inhibitor "paradox" in cancer. Immunology Letters 2008 118 2 116 124 2-s2.0-44649131934 10.1016/j.imlet.2008.03.017
28. Folkman J., Hanahan D., Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symposia 1991 22 339 347 2-s2.0-0026362940
29. Kruithof E. K. O., Regulation of plasminogen activator inhibitor type 1 gene expression by inflammatory mediators and statins. Thrombosis and Haemostasis 2008 100 6 969 975 2-s2.0-57349090664 10.1160/TH08-04-0269
30. Kandouz M., Nie D., Pidgeon G. P., Krishnamoorthy S., Maddipati K. R., Honn K. V., Platelet-type 12-lipoxygenase activates NF- B in prostate cancer cells. Prostaglandins and Other Lipid Mediators 2003 71 3-4 189 204 2-s2.0-0042208268 10.1016/S1098-8823(03)00042-X (Pubitemid 36929790)
31. Kumano M., Miyake H., Muramaki M., Furukawa J., Takenaka A., Fujisawa M., Expression of urokinase-type plasminogen activator system in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urologic Oncology 2009 27 2 180 186 2-s2.0-61649122594 10.1016/j.urolonc.2008.01.012
32. Kwaan H. C., Mazar A. P., McMahon B. J., The apparent uPA/PAI-1 paradox in cancer: more than meets the eye. Seminars in Thrombosis and Hemostasis 2013 39 4 382 391 10.1055/s-0033-1338127
33. Li-Saw-Hee F. L., Blann A. D., Lip G. Y. H., Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation. Stroke 2000 31 4 828 833 2-s2.0-0034037203 (Pubitemid 30198423)
34. McMahon G. S., Jones C. I., Hayes P. D., Naylor A. R., Goodall A. H., Transient heparin-induced platelet activation linked to generation of platelet 12-lipoxygenase. Findings from a randomised controlled trial. Thrombosis and Haemostasis 2013 109 6 1099 1107 10.1160/TH12-11-0793
35. Mehta J. L., Chen J., Yu F., Li D. Y., Aspirin inhibits ox-LDL-mediated LOX-1 expression and metalloproteinase-1 in human coronary endothelial cells. Cardiovascular Research 2004 64 2 243 249 2-s2.0-5444220014 10.1016/j.cardiores. 2004.07.002 (Pubitemid 39361685)
36. Sadowski T., Steinmeyer J., Differential effects of nonsteroidal antiinflammatory drugs on the IL-1 altered expression of plasminogen activators and plasminogen activator inhibitor-1 by articular chondrocytes. Inflammation Research 2002 51 8 427 433 2-s2.0-0036678058
37. Wang Y.-F., Wu W.-J., Zhang M., Zhou M., Li B., Inhibiting cyclooxygenase and 5-lipoxygenase activities is an anti-inflammatory mechanism of Huzhang Gout Granule. Journal of Chinese Integrative Medicine 2009 7 10 963 968 2-s2.0-73849098962 10.3736/jcim20091010
38. Shariat S. F., Semjonow A., Lilja H., Savage C., Vickers A. J., Bjartell A., Tumor markers in prostate cancer I: blood-based markers. Acta Oncologica 2011 50 supplement 1 61 75 2-s2.0-79957461212 10.3109/0284186X.2010.542174
39. Sharma S., Tumor markers in clinical practice: general principles and guidelines. Indian Journal of Medical and Paediatric Oncology 2009 30 1 1 8 10.4103/0971-5851.56328
40. Ohori M., Biomarkers for prostate cancer in predicting diagnosis, staging and prognosis. Cancer & Chemotherapy 2009 36 1 6 10 2-s2.0-60549095293
41. Sturgeon C. M., Duffy M. J., Stenman U.-H., Lilja H., Brünner N., Chan D. W., Babaian R., Bast R. C. Jr., Dowell B., Esteva F. J., Haglund C., Harbeck N., Hayes D. F., Holten-Andersen M., Klee G. G., Lamerz R., Looijenga L. H., Molina R., Nielsen H. J., Rittenhouse H., Semjonow A., Shih I.-M., Sibley P., Sölétormos G., Stephan C., Sokoll L., Hoffman B. R., Diamandis E. P., National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clinical Chemistry 2008 54 12 e11 e79 2-s2.0-55349134617 10.1373/clinchem.2008.105601 (Pubitemid 352777353)
42. Riddick A. C. P., Shukla C. J., Pennington C. J., Bass R., Nuttall R. K., Hogan A., Sethia K. K., Ellis V., Collins A. T., Maitland N. J., Ball R. Y., Edwards D. R., Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. British Journal of Cancer 2005 92 12 2171 2180 2-s2.0-22044445706 10.1038/sj.bjc.6602630 (Pubitemid 40966253)
43. Bohm L., Serafin A., Akudugu J., Fernandez P., van der Merwe A., Aziz N. A., uPA/PAI-1 ratios distinguish benign prostatic hyperplasia and prostate cancer. Journal of Cancer Research and Clinical Oncology 2013 139 7 1221 1228 10.1007/s00432-013-1428-y
44. Piotrowska M., Szefel J., Skrzypczak-Jankun E., Lysiak-Szydlowska W., Szajewski M., Aleksandrowicz-Wrona E., Jankun J., The concentration of 12-lipoxygenase in platelet rich plasma as an indication of cancer of the prostate. Contemporary Oncology 2013 17 4 389 393
45. Festuccia C., Vincentini C., di Pasquale A. B., Aceto G., Zazzeroni F., Miano L., Bologna M., Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma. Oncology Research 1995 7 3-4 131 138 2-s2.0-0029112574
46. McCabe N. P., Angwafo F. F. III, Zaher A., Selman S. H., Kouinche A., Jankun J., Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients. Oncology Reports 2000 7 4 879 882 2-s2.0-0034219455
47. Usher P. A., Thomsen O. F., Iversen P., Johnsen M., Brünner N., Høyer-Hansen G., Andreasen P., Danø K., Nielsen B. S., Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue. International Journal of Cancer 2005 113 6 870 880 2-s2.0-11844272703 10.1002/ijc.20665 (Pubitemid 40096866)
48. Shih S.-J., Dall'Era M. A., Westphal J. R., Yang J., Sweep C. G. J., Gandour-Edwards R., Evans C. P., Elements regulating angiogenesis and correlative microvessel density in benign hyperplastic and malignant prostate tissue. Prostate Cancer and Prostatic Diseases 2003 6 2 131 137 2-s2.0-0038082090 10.1038/sj.pcan.4500637 (Pubitemid 36798380)
49. McCarty M. F., Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy. Integrative Cancer Therapies 2004 3 4 349 380 2-s2.0-9244221653 10.1177/1534735404270757 (Pubitemid 39552429)
50. Kandouz M., Honn K. V., Eicosanoids regulation of transcription factors in PC-3 prostate cancer cells. Advances in Experimental Medicine and Biology 2002 507 563 568 2-s2.0-0037769626 (Pubitemid 37330236)
51. Al-Mondhiry H., Beta-thromboglobulin and platelet-factor 4 in patients with cancer: correlation with the stage of disease and the effect of chemotherapy. American Journal of Hematology 1983 14 2 105 111 2-s2.0-0020638557
52. Dilly A. K., Ekambaram P., Guo Y., Cai Y., Tucker S. C., Fridman R., Kandouz M., Honn K. V., Platelet-type 12-lipoxygenase induces MMP9 expression and cellular invasion via activation of PI3K/Akt/NF-kappaB. International Journal of Cancer 2013 133 8 1784 1791 10.1002/ijc.28165
53. Honn K. V., Aref A., Chen Y. Q., Cher M. L., Crissman J. D., Forman J. D., Gao X., Grignon D., Hussain M., Porter A. T., Pontes J. E., Powell I., Redman B., Sakr W., Severson R., Tang D. G., Wood D. P. Jr., Prostate cancer-old problems and new approaches-part II: diagnostic and prognostic markers, pathology and biological aspects. Pathology & Oncology Research 1996 2 3 191 211 2-s2.0-0010517023
54. Jaśkiewicz K., Izycka-Świeszewska E., Janiak M., Łysiak-Szydłowska W., Adrych K., Reinartz J., Jankun J., Skrzypczak-Jankun E., Platelet 12-lipoxygenase and stem cells in Barrett's esophagus. Oncology Letters 2010 1 5 789 791 2-s2.0-77957557726
55. Krishnamoorthy S., Jin R., Cai Y., Maddipati K. R., Nie D., Pagès G., Tucker S. C., Honn K. V., 12-Lipoxygenase and the regulation of hypoxia-inducible factor in prostate cancer cells. Experimental Cell Research 2010 316 10 1706 1715 2-s2.0-77953230908 10.1016/j.yexcr.2010.03.005
56. Gohara A., Eltaki N., Sabry D., Murtagh D. Jr., Jankun J., Selman S. H., Skrzypczak-Jankun E., Human 5-, 12- and 15-lipoxygenase-1 coexist in kidney but show opposite trends and their balance changes in cancer. Oncology Reports 2012 28 4 1275 1282
57. Singh A. K., Kant S., Parshad R., Banerjee N., Dey S., Evaluation of human LOX-12 as a serum marker for breast cancer. Biochemical and Biophysical Research Communications 2011 414 2 304 308 2-s2.0-80054833641 10.1016/j.bbrc.2011.09.044
58. Dong Z., Saliganan A. D., Meng H., Nabha S. M., Sabbota A. L., Sheng S., Bonfil R. D., Cher M. L., Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover. Neoplasia 2008 10 5 439 449 2-s2.0-43249124467 10.1593/neo.08106 (Pubitemid 351657386)
59. Festuccia C., Dolo V., Guerra F., Violini S., Muzi P., Pavan A., Bologna M., Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells. Clinical and Experimental Metastasis 1998 16 6 513 528 2-s2.0-0032446313 10.1023/A:1006590217724 (Pubitemid 29009587)
60. Shariat S. F., Park S., Trinh Q.-D., Roehrborn C. G., Slawin K. M., Karakiewicz P. I., Plasminogen activation inhibitor-1 improves the predictive accuracy of prostate cancer nomograms. The Journal of Urology 2007 178 4, part 1 1229 1237 2-s2.0-34548452553 10.1016/j.juro.2007.05.161 (Pubitemid 47368420)
61. Croucher D., Saunders D. N., Ranson M., The urokinase/PAI-2 complex: a new high affinity ligand for the endocytosis receptor low density lipoprotein receptor-related protein. The Journal of Biological Chemistry 2006 281 15 10206 10213 2-s2.0-33744512466 10.1074/jbc.M513645200 (Pubitemid 43864557)
62. Dondi D., Festuccia C., Piccolella M., Bologna M., Motta M., GnRH agonists and antagonists decrease the metastatic progression of human prostate cancer cell lines by inhibiting the plasminogen activator system. Oncology Reports 2006 15 2 393 400 2-s2.0-33744485328
63. Nykjaer A., Conese M., Christensen E. I., Olson D., Cremona O., Gliemann J., Blasi F., Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. The EMBO Journal 1997 16 10 2610 2620 2-s2.0-0030926412 10.1093/emboj/16.10.2610 (Pubitemid 27226200)
64. Epstein J. I., Allsbrook W. C. Jr., Amin M. B., Egevad L. L., Bastacky S., López Beltrán A., Berner A., Billis A., Boccon-Gibod L., Cheng L., Civantos F., Cohen C., Cohen M. B., Datta M., Davis C., Delahunt B., Delprado W., Eble J. N., Foster C. S., Furusato M., Gaudin P. B., Grignon D. J., Humphrey P. A., Iczkowski K. A., Jones E. C., Lucia S., McCue P. A., Nazeer T., Oliva E., Pan C.-C., Pizov G., Reuter V., Samaratunga H., Sebo T., Sesterhenn I., Shevchuk M., Srigley J. R., Suzigan S., Takahashi H., Tamboli P., Tan P. H., Tètu B., Tickoo S., Tomaszewski J. E., Troncoso P., Tsuzuki T., True L. D., Van Der Kwast T., Wheeler T. M., Wojno K. J., Young R. H., The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. The American Journal of Surgical Pathology 2005 29 9 1228 1242 2-s2.0-24144493035 10.1097/01.pas.0000173646. 99337.b1 (Pubitemid 41232997)